Last reviewed · How we verify
Local standard venous thromboprophylaxis
Local standard venous thromboprophylaxis prevents blood clots in veins through established anticoagulant or mechanical methods applied according to institutional protocols.
Local standard venous thromboprophylaxis prevents blood clots in veins through established anticoagulant or mechanical methods applied according to institutional protocols. Used for Venous thromboembolism prophylaxis in hospitalized patients, Post-operative thromboprophylaxis.
At a glance
| Generic name | Local standard venous thromboprophylaxis |
|---|---|
| Sponsor | UMC Utrecht |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This refers to a standardized institutional approach to preventing venous thromboembolism (VTE), typically combining pharmacological anticoagulants (such as low-molecular-weight heparin or fondaparinux) with mechanical methods (compression stockings or sequential compression devices). The specific mechanism depends on the local protocol at UMC Utrecht and the patient population being treated.
Approved indications
- Venous thromboembolism prophylaxis in hospitalized patients
- Post-operative thromboprophylaxis
Common side effects
- Bleeding
- Heparin-induced thrombocytopenia (HIT)
- Injection site reactions
Key clinical trials
- Delivery and Implementation of a Randomised Crossover Trial on Thrombosis (NA)
- Comparison of 2 Low Molecular Weight Heparin as a Thromboprophylaxis Postpartum (NA)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial (PHASE3)
- Heparin Anticoagulation in Septic Shock (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Local standard venous thromboprophylaxis CI brief — competitive landscape report
- Local standard venous thromboprophylaxis updates RSS · CI watch RSS
- UMC Utrecht portfolio CI